DK1026950T3 - Behandling af skizofreni med ampakiner og neuroleptika - Google Patents

Behandling af skizofreni med ampakiner og neuroleptika

Info

Publication number
DK1026950T3
DK1026950T3 DK98957382T DK98957382T DK1026950T3 DK 1026950 T3 DK1026950 T3 DK 1026950T3 DK 98957382 T DK98957382 T DK 98957382T DK 98957382 T DK98957382 T DK 98957382T DK 1026950 T3 DK1026950 T3 DK 1026950T3
Authority
DK
Denmark
Prior art keywords
schizophrenia
treatment
ampakines
neuroleptics
relates
Prior art date
Application number
DK98957382T
Other languages
Danish (da)
English (en)
Inventor
Steven A Johnson
Gary A Rogers
Gary S Lynch
Original Assignee
Univ California
Cortex Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22050462&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1026950(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ California, Cortex Pharma Inc filed Critical Univ California
Application granted granted Critical
Publication of DK1026950T3 publication Critical patent/DK1026950T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Hydrogenated Pyridines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK98957382T 1997-10-27 1998-10-26 Behandling af skizofreni med ampakiner og neuroleptika DK1026950T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6362797P 1997-10-27 1997-10-27

Publications (1)

Publication Number Publication Date
DK1026950T3 true DK1026950T3 (da) 2006-06-26

Family

ID=22050462

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98957382T DK1026950T3 (da) 1997-10-27 1998-10-26 Behandling af skizofreni med ampakiner og neuroleptika

Country Status (15)

Country Link
US (1) US6166008A (de)
EP (1) EP1026950B1 (de)
JP (1) JP2001520978A (de)
CN (1) CN1281335A (de)
AT (1) ATE317226T1 (de)
AU (1) AU745641B2 (de)
BR (1) BR9814106A (de)
CA (1) CA2306817A1 (de)
CY (1) CY1105557T1 (de)
DE (1) DE69833451T2 (de)
DK (1) DK1026950T3 (de)
ES (1) ES2258825T3 (de)
HK (1) HK1030338A1 (de)
PT (1) PT1026950E (de)
WO (1) WO1999021422A1 (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2210060T3 (es) 1992-07-24 2004-07-01 The Regents Of The University Of California Farmacos que aumentan las respuestas sinapticas mediadas por receptores ampa.
WO2002096431A1 (en) * 2001-05-25 2002-12-05 The Regents Of The University Of California Optically active compounds clearing malformed proteins
US20040229898A1 (en) * 2001-05-25 2004-11-18 The Regents Of The University Of California Cyclic bis-compounds clearing malformed proteins
WO2003014321A2 (en) * 2001-08-10 2003-02-20 The Rockefeller University Compositions and methods for modulation of darpp-32 phosphorylation
UA80317C2 (en) * 2003-01-13 2007-09-10 Cortex Pharma Inc Method of treating cognitive decline due to sleep deprivation and stress
WO2005013961A1 (en) * 2003-07-17 2005-02-17 Eli Lilly And Company Combination therapy for treatment of cognitive disorders or psychoses
NZ527142A (en) * 2003-07-23 2006-03-31 Douglas Pharmaceuticals Ltd A stable suspension formulation
AU2004270162B2 (en) * 2003-08-28 2010-05-13 Nicox S.A. Nitrosated ad nitrosylated diuretic compouds, compositions and methods of use
GB0325175D0 (en) * 2003-10-28 2003-12-03 Novartis Ag Organic compounds
AU2005208871B2 (en) * 2004-01-26 2010-04-01 Cortex Pharmaceuticals Inc. Enhancement of ampakine-induced facilitation of synaptic responses by cholinesterase inhibitors
EP1766077B1 (de) 2004-06-21 2012-03-28 The Board Of Trustees Of The Leland Stanford Junior University Bei manisch-depressiver erkrankung und/oder schwerer depressiver erkrankung unterschiedlich exprimierte gene und wege
US20060063707A1 (en) * 2004-09-17 2006-03-23 Lifelike Biomatic, Inc. Compositions for enhancing memory and methods therefor
US20060069086A1 (en) * 2004-09-23 2006-03-30 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
CA2597460A1 (en) 2005-02-24 2006-08-31 Nitromed, Inc. Nitric oxide enhancing diuretic compounds, compositions and methods of use
RS52715B (en) 2005-04-13 2013-08-30 Astex Therapeutics Limited HYDROXYBENZAMIDE DERIVATIVES AND THEIR APPLICATIONS AS HSP90 INHIBITORS
KR20060119373A (ko) * 2005-05-20 2006-11-24 엘지전자 주식회사 컴퓨터 시스템과 시스템 소프트웨어 설치방법 및 휴대용컴퓨터의 소프트웨어 설치방법
WO2007059064A2 (en) 2005-11-12 2007-05-24 The Board Of Trustees Of The Leland Stanford Junior University Fgf2-related methods for diagnosing and treating depression
US20090286797A1 (en) * 2005-11-22 2009-11-19 Dan Peters Novel Quinoxaline Derivatives and Their Medical Use
US7754725B2 (en) 2006-03-01 2010-07-13 Astex Therapeutics Ltd. Dihydroxyphenyl isoindolymethanones
US20080176793A1 (en) * 2006-09-18 2008-07-24 The Regents Of The University Of California Upregulating activity or expression of bdnf to mitigate cognitive impairment in asymptomatic huntington's subjects
JP5528807B2 (ja) 2006-10-12 2014-06-25 アステックス、セラピューティックス、リミテッド 複合薬剤
GB0620259D0 (en) 2006-10-12 2006-11-22 Astex Therapeutics Ltd Pharmaceutical compounds
EP2081891A2 (de) 2006-10-12 2009-07-29 Astex Therapeutics Limited Pharmazeutische verbindungen mit hsp90-hemmender oder modulierender wirkung
JP5518478B2 (ja) 2006-10-12 2014-06-11 アステックス、セラピューティックス、リミテッド 医薬化合物
US8916552B2 (en) 2006-10-12 2014-12-23 Astex Therapeutics Limited Pharmaceutical combinations
EP2073802A1 (de) 2006-10-12 2009-07-01 Astex Therapeutics Limited Pharmazeutische kombinationen
US8198305B2 (en) * 2007-04-13 2012-06-12 Concert Pharmaceuticals Inc. 1,2-benzisoxazol-3-yl compounds
US20090006902A1 (en) * 2007-06-29 2009-01-01 International Business Machines Corporation Methods, systems, and computer program products for reporting fru failures in storage device enclosures
US8119632B2 (en) 2007-08-10 2012-02-21 Cortex Pharmaceuticals, Inc. Bicyclic amide derivatives for enhancing glutamatergic synaptic responses
AU2008287445A1 (en) 2007-08-10 2009-02-19 Cortex Pharmaceuticals, Inc. Bicyclic amides for enhancing glutamatergic synaptic responses
US8071914B2 (en) * 2007-12-26 2011-12-06 Noboru Oshima Heating apparatus
GB0806527D0 (en) 2008-04-11 2008-05-14 Astex Therapeutics Ltd Pharmaceutical compounds
SG173168A1 (en) * 2009-02-02 2011-08-29 Cortex Pharma Inc Bicyclic amide derivatives for enhancing glutamatergic synaptic responses
PT105083A (pt) 2009-04-28 2011-07-25 Univ De Coimbra Processo para cultura de células estaminais neurais baseado nas ampacinas e/ou outros moduladores de receptores glutamatérgicos ionotrópicos, composições e seu uso em condições do sistema nervoso central
EP2544688B1 (de) 2010-03-02 2016-09-07 President and Fellows of Harvard College Verfahren und zusammensetzungen zur behandlung des angelman-syndroms
CA2829006A1 (en) 2011-03-04 2012-09-13 The Regents Of The University Of California Locally released growth factors to mediate motor recovery after stroke
US8822464B2 (en) 2011-11-28 2014-09-02 Boehringer Ingelheim International Gmbh N-aryl-piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors
US8741892B2 (en) * 2011-12-05 2014-06-03 Boehringer Ingelheim International Gmbh Compounds
US8796467B2 (en) 2011-12-13 2014-08-05 Boehringer Ingelheim International Gmbh Compounds
US8846948B2 (en) 2011-12-13 2014-09-30 Boehringer Ingelheim International Gmbh Compounds
US8883789B2 (en) 2011-12-14 2014-11-11 Boehringer Ingelheim International Gmbh Piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors
US8937176B2 (en) 2011-12-14 2015-01-20 Boehringer Ingelheim International Gmbh Compounds
US8716277B2 (en) 2011-12-14 2014-05-06 Boehringer Ingelheim International Gmbh Substituted imidazole compounds useful as positive allosteric modulators of mGlu5 receptor activity
US8889677B2 (en) 2012-01-17 2014-11-18 Boehringer Ingellheim International GmbH Substituted triazoles useful as mGlu5 receptor modulators
DK2854836T3 (en) 2012-06-05 2018-06-18 Univ Leland Stanford Junior NCAM peptide mimetics for use in the treatment of depression
SG11202009438UA (en) 2018-04-18 2020-11-27 Constellation Pharmaceuticals Inc Modulators of methyl modifying enzymes, compositions and uses thereof
CA3100977A1 (en) 2018-05-21 2019-11-28 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8908085D0 (en) * 1989-04-11 1989-05-24 Lundbeck & Co As H New therapeutic use
US5312819A (en) * 1990-08-20 1994-05-17 Sandoz Ltd. Pharmaceutical compositions comprising clozapine and a radical scavenger
US5447948A (en) * 1992-05-07 1995-09-05 Yale University Dopamine and noradrenergic reuptake inhibitors in treatment of schizophrenia
GB9507230D0 (en) * 1995-04-07 1995-05-31 Inst Of Psychiatry Novel method
US5650409A (en) * 1995-06-02 1997-07-22 Cortex Pharmaceuticals, Inc. Benzoyl piperidines/pyrrolidines for enhancing synaptic response
US5773434A (en) * 1995-08-30 1998-06-30 Gary A. Rogers Facilitation of AMPA receptor-mediated synaptic transmission in brain as a treatment for schizophrenia
US5736543A (en) * 1996-04-03 1998-04-07 The Regents Of The University Of California Benzoxazines for enhancing synaptic response

Also Published As

Publication number Publication date
EP1026950B1 (de) 2006-02-08
HK1030338A1 (en) 2001-05-04
DE69833451T2 (de) 2006-09-28
ATE317226T1 (de) 2006-02-15
AU745641B2 (en) 2002-03-28
US6166008A (en) 2000-12-26
ES2258825T3 (es) 2006-09-01
WO1999021422A1 (en) 1999-05-06
CY1105557T1 (el) 2010-07-28
JP2001520978A (ja) 2001-11-06
DE69833451D1 (de) 2006-04-20
CN1281335A (zh) 2001-01-24
EP1026950A4 (de) 2004-07-07
BR9814106A (pt) 2000-10-03
AU1365899A (en) 1999-05-17
CA2306817A1 (en) 1999-05-06
EP1026950A1 (de) 2000-08-16
PT1026950E (pt) 2006-06-30

Similar Documents

Publication Publication Date Title
DK1026950T3 (da) Behandling af skizofreni med ampakiner og neuroleptika
DE60024588D1 (de) Substituierte porphyrine und deren therapeutische verwendungen
DE69429524D1 (de) Aminocyclohexylester und ihre anwendung
DE69813898D1 (de) Substituierte porphyrinen
SE9900100D0 (sv) New compounds
MXPA04004714A (es) Derivados de aril 1,4-pirazina sustituidos.
MY130489A (en) Substituted aryl 1, 4-pyrazine derivatives
TR200002773T2 (tr) Alzheimer tedavisi için smilagenin ve anzurogenin-D ve bunların kullanımı.
NO306779B1 (no) Naftalamider, anvendelse derav og farmasöytisk preparat
DK0876818T3 (da) Middel til behnadling af nerodegenerative lidelser
ATE430742T1 (de) Pyrimidinamine als angiogenesemodulatoren
NO20061845L (no) Fenyl-piperazinderivater som modulatorer for muskarine reseptorer
JO2359B1 (en) Benzathene derivatives as agents for modulation of GABA A receptor
NO20000521D0 (no) 1-(N-fenylaminoalkyl)-piperazin derivater substituert i posisjon 2 på fenylringen
ATE288747T1 (de) Methoden und zusammensetzungen zur modulierung der aktivität von alpha-adrenergen rezeptoren
DK1097173T3 (da) Anvendelse af peptider af IL-2 og derivater deraf som terapeutiske midler
DK0556332T3 (da) Substituerede tetrahydropyridiner og hydroxypiperidiner som midler til behandling af centralnervesystemet
DE60025639D1 (de) Substituierte diazepan
PT1000046E (pt) Derivados de piperazina activos no trato urinario inferior
TW200503717A (en) Substituted 1,4-pyrazine derivatives
TR200200278T2 (tr) Kalsilitik bileşimler
ES2140672T3 (es) Compuestos biciclicos sustituidos, fusionados y puentes utilizados como agentes terapeuticos.
NZ511997A (en) Isonipecotamides for the treatment of integrin-mediated disorders
TR200000916T2 (tr) İkameli piperidin türevleri.